Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 1223-1230, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Houbouyan, L.
Right arrow Articles by Gourmelin, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Houbouyan, L.
Right arrow Articles by Gourmelin, Y.

Clinical Chemistry, Vol 42, 1223-1230, Copyright © 1996 by American Association for Clinical Chemistry

Validation protocol of analytical hemostasis systems: measurement of anti-Xa activity of low-molecular-weight heparins

L Houbouyan, B Boutiere, G Contant, MD Dautzenberg, P Fievet, G Potron, A Vassault and Y Gourmelin
Department of Hematology, Hopital A. Pare, Boulogne, France.

A standard validation protocol adapted to the chromogenic assay of anti- Xa activity of low-molecular-weight heparins was used in a multicenter study to assess its suitability for comparing and evaluating analytical hemostasis systems. The protocol included: familiarization with the system (repeatability); assessment of limits of linearity, detection limits, and cross-contamination; and validation (reproducibility and accuracy of measurements of treated patients' plasmas). We calibrated the systems with the same range of lyophilized plasmas daily and evaluated repeatability and reproducibility by using a single batch of lyophilized plasmas at three anti-Xa activities. The two automated systems tested [SB 300 (Gilford) and ACL (IL)] and the two semiautomated systems [ST 888 (D. Stago) and Chromotimer (Behring)] gave similar mean values. Dispersion of results was lower with the automated systems than with the semiautomated ones, especially at low anti-Xa activities, a tendency that also was observed for reproducibility. Because each analytical system gave linear results for activities as great as 1000 IU/L, suitable sample dilution is advisable for higher anti-Xa activities. Accuracy was greater in the automated systems. We conclude that this protocol is feasible and is applicable to validation of other analytical hemostasis instruments, in particular the latest generation of fully automated instruments.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
P. H. Petersen, D. Stockl, O. Blaabjerg, B. Pedersen, E. Birkemose, L. Thienpont, J. F. Lassen, and J. Kjeldsen
Graphical interpretation of analytical data from comparison of a field method with a Reference Method by use of difference plots
Clin. Chem., November 1, 1997; 43(11): 2039 - 2046.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.